NCT06222125View on ClinicalTrials.gov

A Study of HB0025 Injection in Patients With Advanced Renal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 30, 2023

Primary Completion Date

January 30, 2025

Study Completion Date

December 30, 2025

Conditions
Renal Cancer
Interventions
DRUG

HB0025

HB0025 IV every 2 weeks (q2w)

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

Sponsors
All Listed Sponsors
lead

Huabo Biopharm Co., Ltd.

INDUSTRY